Cerner Confirms The Agreement To Buy The Kantar Health Division
Combination to build leading knowledge and forum for clinical science industry-leading experience in clinical science development and de-identified real-world evidence
Cerner Corporation announced today that they would purchase the $375 million cash modification deal of Kantar Wellness, a subsidiary of Kantar Group. Kantar Health is a leading market research consultancy, results, studies, and facts from the realm of life science. This acquisition would enable Cerner to leverage data to enhance the protection, quality, and effectiveness of clinical research in the life sciences, pharmaceuticals, and health care sectors as a whole. Cerner’s Health Network SM consortium is intended to collaborate more closely in life sciences to support scientific programs. It is expected to be an acquisition.
“Cerner has started with our providers a Learning Health Network to promote a common vision: to better treat global diseases by accelerating clinical research,” says Donald Trigg, president of Cerner. “Kantar Health has unbelievable health and medical experience, distinct data properties, and close links with leading life science companies worldwide. It gives us a great opportunity to foster cross-industry partnership which can change global health outcomes.”
The Cerner Learning Health Network provides health institutions with complimentary access to a bi-directionally deidentified data network with the goal of revolutionizing clinical science. This access helps support scientific activities and generates profits from funded research by life science corporations. Today, Kantar Health is used by all the top 20 organizations in the life sciences to further their real-world facts, market, and clinical testing activities through its own syndicated patented data-products like CancerMPact®, Claritis, national health & wellness survey and wider oncology, rare diseases and multitherapeutic skills.
The integration of Cerner and Kantar Health is expected to allow two-sided coordination between pharmaceuticals and providers, where researchers are able to produce knowledge and use specialized data and experience in the real world to cope with the most difficult questions in clinical science.
“We are proud of the legacy and prestige of Kantar Health as advisors to the leading life scientific producers in the world. We look forward to this chapter in which Cerner will be the force behind our real-world proof and commercial knowledge,” says Lynnette Cooke, CEO of Kantar Health. “Both organizations have a good cultural match based on our common mission of increasing patient access and cost-effectiveness worldwide. It is expected that integrating our experience and assets with Cerner’s technologies and new insights into patients would enable a progressive shift in how we create and provide healthcare that results in healthier outcomes for patients.”
The acquisition is anticipated to close in the first half of 2021, subject to regulatory approval, employee consultations, and other conditions, and is not expected to have a material impact on Cerner’s earnings in 2021.
Harris Williams acted as exclusive financial advisor; Weil, Gotshal & Manges LLP acted as a legal advisor; and EY acted as accounting, tax, operational, technology, and separation advisors to Kantar Health.
Latham & Watkins LLP acted as a legal advisor; EY provided financial, tax, and HR due diligence; and its EY-Parthenon consulting practice acted as strategic, commercial, and operational advisors to Cerner.